" class="no-js "lang="en-US"> Etienne Montagut - Medtech Alert
Saturday, August 02, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Etienne Montagut

Etienne Montagut

About Etienne Montagut

Business leader with expertise in general management, portfolio management, BD and sales & marketing
• Strong adaptation and learning skills demonstrated in various cross-functional and cross-geographical experiences
• Pragmatic, result oriented and creative

Specialties:
Business turn around and portfolio/pipeline buildup:
P&L and General Management
Product Portfolio Management
Business Development & Licensing
Sales & marketing operations
Alternative funding of R&D programs
Design, development and commercialization of Digital Solutions (diagnostic)
MI Biomarker development and Pharma Services
Business expansion in China, Europe and North America

Related Story

Clinical Trials

 Radiopharm Enters Into Strategic Collaboration With Lantheus and Assumes PD-L1 Licensing Agreement From Nanomab | Pharmtech Focus

Radiopharm Enters Into Strategic Collaboration With Lantheus and Assumes PD-L1 Licensing Agreement From Nanomab

August 4 2022

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical […]